141 related articles for article (PubMed ID: 22029619)
1. Outcome of opioid switching 4 weeks after discharge from a palliative care unit.
Mercadante S; Ferrera P; Casuccio A
Curr Med Res Opin; 2011 Dec; 27(12):2357-60. PubMed ID: 22029619
[TBL] [Abstract][Full Text] [Related]
2. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
[TBL] [Abstract][Full Text] [Related]
3. Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit.
Mercadante S
Pain Med; 2012 Mar; 13(3):399-404. PubMed ID: 22360828
[TBL] [Abstract][Full Text] [Related]
4. Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?
Mercadante S; Villari P; Ferrera P; Casuccio A
Eur J Pain; 2006 Feb; 10(2):153-9. PubMed ID: 16310719
[TBL] [Abstract][Full Text] [Related]
5. Opioid switching in patients with advanced cancer followed at home. A retrospective analysis.
Mercadante S; Valle A; Porzio G; Fusco F; Aielli F; Adile C; Casuccio A;
J Pain Symptom Manage; 2013 Feb; 45(2):298-304. PubMed ID: 23102561
[TBL] [Abstract][Full Text] [Related]
6. The use of high doses of OROS hydromorphone in an acute palliative care unit.
Mercadante S
Curr Med Res Opin; 2011 Dec; 27(12):2373-6. PubMed ID: 22077957
[TBL] [Abstract][Full Text] [Related]
7. Rapid switching between transdermal fentanyl and methadone in cancer patients.
Mercadante S; Ferrera P; Villari P; Casuccio A
J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965
[TBL] [Abstract][Full Text] [Related]
8. The use of high doses of oxycodone in an acute palliative care unit.
Mercadante S; Ferrera P; David F; Casuccio A
Am J Hosp Palliat Care; 2011 Jun; 28(4):242-4. PubMed ID: 20826490
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids.
Mercadante S; Intravaia G; Villari P; Ferrera P; Riina S; David F; Mangione S
Clin J Pain; 2007; 23(9):793-8. PubMed ID: 18075407
[TBL] [Abstract][Full Text] [Related]
10. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids.
Mercadante S; Porzio G; Aielli F; Adile C; Verna L; Ficorella C; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jun; 29(6):661-6. PubMed ID: 23540512
[TBL] [Abstract][Full Text] [Related]
11. The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.
Mercadante S; Villari P; Ferrera P; Mangione S; Casuccio A
Clin J Pain; 2010 May; 26(4):306-9. PubMed ID: 20393265
[TBL] [Abstract][Full Text] [Related]
12. Optimization of opioid therapy for preventing incident pain associated with bone metastases.
Mercadante S; Villari P; Ferrera P; Casuccio A
J Pain Symptom Manage; 2004 Nov; 28(5):505-10. PubMed ID: 15504626
[TBL] [Abstract][Full Text] [Related]
13. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
14. Comparison of opioid requirements and analgesic response in opioid-tolerant versus opioid-naïve patients after total knee arthroplasty.
Patanwala AE; Jarzyna DL; Miller MD; Erstad BL
Pharmacotherapy; 2008 Dec; 28(12):1453-60. PubMed ID: 19025426
[TBL] [Abstract][Full Text] [Related]
15. Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study.
Mercadante S; Intravaia G; Villari P; Ferrera P; Riina S; Mangione S
J Pain Symptom Manage; 2008 Mar; 35(3):307-13. PubMed ID: 18178368
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.
Mercadante S; Villari P; Ferrera P; Bianchi M; Casuccio A
J Pain Symptom Manage; 2004 Apr; 27(4):352-9. PubMed ID: 15050663
[TBL] [Abstract][Full Text] [Related]
17. Opioid switch in palliative care, opioid choice by clinical need and opioid availability.
Müller-Busch HC; Lindena G; Tietze K; Woskanjan S
Eur J Pain; 2005 Oct; 9(5):571-9. PubMed ID: 16139186
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
19. [Pain treatment of patients with incurable malignant tumors].
Schwarzer A; Klaschik E; Nauck F
Dtsch Med Wochenschr; 2005 Nov; 130(45):2561-5. PubMed ID: 16273495
[TBL] [Abstract][Full Text] [Related]
20. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
